The serostim market research report is one of a series of new reports that provides serostim market statistics, including serostim industry global market size, regional shares, competitors with a serostim market share, detailed serostim market segments, market trends and opportunities, and any further data you may need to thrive in the serostim industry. This serostim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising incidence and prevalence of cancer, growing prevalence of growth hormone deficiency, rising healthcare spending, rising number of clinical trials, and rising prevalence of antiretroviral therapy side effects. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, the adoption of digital tools, and hormone therapies.
The increasing incidence of HIV/AIDS is expected to drive the growth of the Serostim market in the future. HIV/AIDS is a viral infection that compromises the immune system, and without treatment, it can progress to acquired immunodeficiency syndrome (AIDS). The rise in HIV/AIDS cases is influenced by factors such as unprotected sex, limited healthcare access, lack of awareness, and stigma, all of which facilitate the virus's spread. Serostim assists HIV/AIDS patients by promoting weight gain, increasing lean body mass, and improving physical strength, which helps counter the effects of HIV-related wasting and enhances overall quality of life. For example, the UK Health Security Agency reported in October 2024 that new HIV diagnoses in England reached 6,008 in 2023, a 51% increase compared to the 3,975 recorded in 2022. As a result, the rising incidence of HIV/AIDS is contributing to the growth of the Serostim market.
The expansion of healthcare infrastructure is also expected to boost the Serostim market. Healthcare infrastructure includes essential facilities, resources, and systems, such as hospitals, clinics, medical equipment, and healthcare professionals, required to deliver quality care. This expansion is driven by factors such as a growing global population, an aging demographic, and rapid urbanization. The development of healthcare infrastructure supports the use of Serostim by providing necessary medical facilities, diagnostic tools, and treatment frameworks to ensure proper administration, monitor patient outcomes, and facilitate effective management of HIV-associated wasting. For instance, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, marking a 0.591% increase from the previous year's total of 6,093 hospitals. Consequently, the expansion of healthcare infrastructure is helping to drive the growth of the Serostim market.
The growing prevalence of target diseases is also expected to drive the growth of the Serostim market. Target diseases are specific conditions that are the focus of treatment, intervention, or research due to their widespread occurrence or severity. The increasing prevalence of these diseases is driven by factors such as aging populations, unhealthy lifestyle choices, environmental influences, and improved detection methods. Serostim aids in reversing or preventing muscle wasting and lean body mass loss by stimulating growth hormone receptors to enhance protein synthesis, which helps rebuild muscle and tissue. For instance, the Centers for Disease Control and Prevention reported in March 2024 that the number of tuberculosis cases in the United States increased from 8,320 in 2022 to 9,615 in 2023, showing a rise of 1,295 cases. As a result, the increasing prevalence of target diseases is fueling the growth of the Serostim market.
The key company operating in the serostim market is EMD Serono Inc.
North America was the largest region in the serostim market in 204. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in serostim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Serostim is a recombinant human growth hormone (somatropin) specifically formulated to treat HIV-associated wasting or cachexia. It helps improve body weight, lean body mass, and physical endurance in patients who experience significant weight loss due to HIV.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Serostim include HIV-associated wasting syndrome and cachexia. HIV-associated wasting syndrome is a condition in which individuals with HIV experience substantial weight loss, muscle wasting, and a decline in overall health due to the virus's effects on the body. Serostim is distributed through channels such as direct sales, pharmacies, and wholesalers. It is used in various end-use settings, including hospitals, clinics, ambulatory care, and home care.
The serostim consists of sales of lyophilized powder for injection, pre-filled syringes, and cartridge formulations for injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising incidence and prevalence of cancer, growing prevalence of growth hormone deficiency, rising healthcare spending, rising number of clinical trials, and rising prevalence of antiretroviral therapy side effects. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, the adoption of digital tools, and hormone therapies.
The increasing incidence of HIV/AIDS is expected to drive the growth of the Serostim market in the future. HIV/AIDS is a viral infection that compromises the immune system, and without treatment, it can progress to acquired immunodeficiency syndrome (AIDS). The rise in HIV/AIDS cases is influenced by factors such as unprotected sex, limited healthcare access, lack of awareness, and stigma, all of which facilitate the virus's spread. Serostim assists HIV/AIDS patients by promoting weight gain, increasing lean body mass, and improving physical strength, which helps counter the effects of HIV-related wasting and enhances overall quality of life. For example, the UK Health Security Agency reported in October 2024 that new HIV diagnoses in England reached 6,008 in 2023, a 51% increase compared to the 3,975 recorded in 2022. As a result, the rising incidence of HIV/AIDS is contributing to the growth of the Serostim market.
The expansion of healthcare infrastructure is also expected to boost the Serostim market. Healthcare infrastructure includes essential facilities, resources, and systems, such as hospitals, clinics, medical equipment, and healthcare professionals, required to deliver quality care. This expansion is driven by factors such as a growing global population, an aging demographic, and rapid urbanization. The development of healthcare infrastructure supports the use of Serostim by providing necessary medical facilities, diagnostic tools, and treatment frameworks to ensure proper administration, monitor patient outcomes, and facilitate effective management of HIV-associated wasting. For instance, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, marking a 0.591% increase from the previous year's total of 6,093 hospitals. Consequently, the expansion of healthcare infrastructure is helping to drive the growth of the Serostim market.
The growing prevalence of target diseases is also expected to drive the growth of the Serostim market. Target diseases are specific conditions that are the focus of treatment, intervention, or research due to their widespread occurrence or severity. The increasing prevalence of these diseases is driven by factors such as aging populations, unhealthy lifestyle choices, environmental influences, and improved detection methods. Serostim aids in reversing or preventing muscle wasting and lean body mass loss by stimulating growth hormone receptors to enhance protein synthesis, which helps rebuild muscle and tissue. For instance, the Centers for Disease Control and Prevention reported in March 2024 that the number of tuberculosis cases in the United States increased from 8,320 in 2022 to 9,615 in 2023, showing a rise of 1,295 cases. As a result, the increasing prevalence of target diseases is fueling the growth of the Serostim market.
The key company operating in the serostim market is EMD Serono Inc.
North America was the largest region in the serostim market in 204. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in serostim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Serostim is a recombinant human growth hormone (somatropin) specifically formulated to treat HIV-associated wasting or cachexia. It helps improve body weight, lean body mass, and physical endurance in patients who experience significant weight loss due to HIV.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Serostim include HIV-associated wasting syndrome and cachexia. HIV-associated wasting syndrome is a condition in which individuals with HIV experience substantial weight loss, muscle wasting, and a decline in overall health due to the virus's effects on the body. Serostim is distributed through channels such as direct sales, pharmacies, and wholesalers. It is used in various end-use settings, including hospitals, clinics, ambulatory care, and home care.
The serostim consists of sales of lyophilized powder for injection, pre-filled syringes, and cartridge formulations for injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Serostim Market Characteristics4. Serostim Market Trends And Strategies5. Serostim Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Serostim Pricing Analysis & Forecasts30. Global Serostim Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Serostim Market32. Recent Developments In The Serostim Market
3. Serostim Market Biologic Drug Characteristics
6. Global Serostim Growth Analysis And Strategic Analysis Framework
8. Serostim Market Segmentation
9. Global Serostim Epidemiology Of Clinical Indications
10. Serostim Market Regional And Country Analysis
11. Asia-Pacific Serostim Market
12. China Serostim Market
13. India Serostim Market
14. Japan Serostim Market
15. Australia Serostim Market
16. South Korea Serostim Market
17. Western Europe Serostim Market
18. UK Serostim Market
19. Germany Serostim Market
20. France Serostim Market
21. Eastern Europe Serostim Market
22. North America Serostim Market
23. USA Serostim Market
24. Canada Serostim Market
25. South America Serostim Market
26. Middle East Serostim Market
27. Africa Serostim Market
28. Serostim Market Competitive Landscape And Company Profiles
29. Global Serostim Market Pipeline Analysis
33. Serostim Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Serostim Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on serostim market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for serostim ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The serostim market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: HIV-Associated Wasting Syndrome; Cachexia2) By Distribution Channel: Direct Sales; Pharmacies; Wholesalers
3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: EMD Serono Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- EMD Serono Inc.
